Clinical trials are the bridge between scientific discovery and new medical treatments. Yet designing and conducting them remains complex, expensive, and time-consuming.

One of the biggest challenges is identifying the right patients and determining which outcomes can most accurately demonstrate whether a treatment works.

Artificial intelligence (AI) is beginning to change both processes.

Machine learning, deep learning, natural language processing, generative AI, and multimodal analytics can analyze information from electronic health records, medical imaging, genomic data, laboratory results, clinical-trial protocols, and other sources.

The goal is not simply to automate clinical research. Increasingly, researchers are exploring whether AI can help design more precise trials, identify appropriate participants, reduce recruitment barriers, improve endpoint selection, and support adaptive decision-making.

A recent scoping review identified applications of AI and machine learning across clinical-trial design, participant stratification, treatment selection, participant selection, outcome assessment, and site selection, although the authors also found that real-world adoption remains well behind the technology's potential.

At the same time, regulatory agencies are establishing frameworks for responsible AI use. The FDA and EMA have developed guiding principles emphasizing human oversight, context of use, data governance, performance assessment, and lifecycle management for AI used in drug development.

The result is a new phase of clinical research in which AI could influence decisions from trial protocol design to patient enrollment and endpoint analysis. For broader context on AI's role in healthcare, see The Role of Artificial Intelligence in Medical Research.

What Is AI-Powered Clinical Trial Design?

AI-powered clinical trial design refers to using computational models to support decisions involved in planning, recruiting, conducting, monitoring, or analyzing clinical studies.

Traditional trial design relies heavily on statistical models, historical evidence, expert judgment, and predefined assumptions.

AI can complement these approaches by processing much larger and more complex datasets.

For example, an AI system could analyze historical clinical-trial data and real-world patient records to identify:

  • Which patients are most likely to meet eligibility criteria
  • Which characteristics are associated with treatment response
  • Which patients may be at higher risk of adverse events
  • Which endpoints are likely to show meaningful treatment effects
  • Which trial sites are likely to recruit successfully
  • Where enrollment bottlenecks may occur
  • Which patient subgroups may require separate analysis

Importantly, AI does not replace statistical methodology or clinical expertise. Instead, its most valuable role may be to help researchers make better-informed decisions before and during a trial.

Why Patient Stratification Matters

Patient stratification is one of the most important components of modern clinical research.

Patients with the same diagnosis may have very different biological characteristics.

For example, two people with the same cancer type could have different:

  • Genetic mutations
  • Biomarker profiles
  • Disease stages
  • Immune responses
  • Comorbidities
  • Treatment histories
  • Disease trajectories

If these differences are ignored, a clinical trial may fail to detect a treatment effect that exists only in a specific subgroup.

AI can help researchers identify these patterns. Instead of treating a patient population as a single homogeneous group, machine-learning models can analyze multiple variables simultaneously and identify clinically meaningful subgroups.

This approach is especially relevant to precision medicine.

Medical Journal IMJ Health Call for Papers

How AI Improves Patient Stratification

1. Multimodal Patient Profiling

Modern clinical datasets are increasingly multimodal.

A single patient may generate information from:

  • Electronic health records
  • Genomic sequencing
  • Medical imaging
  • Pathology
  • Laboratory tests
  • Wearable devices
  • Patient-reported outcomes
  • Medication histories
  • Demographic information

Traditional analysis may struggle to integrate all of these variables simultaneously.

AI models can identify relationships across different data types. For example, an oncology trial could potentially combine imaging characteristics with genomic biomarkers and clinical history to identify patients more likely to respond to an investigational therapy.

The result could be a more biologically defined study population.

2. AI-Powered Eligibility Screening

One of the practical barriers to patient enrollment is determining whether an individual meets complex eligibility criteria.

Researchers often need to manually review electronic health records to determine whether a patient qualifies. This can be slow and prone to missed opportunities.

A 2026 randomized evaluation published in Nature Communications examined human-AI collaboration for prescreening oncology patients against clinical-trial eligibility criteria. The study highlighted manual prescreening as a time-consuming bottleneck and evaluated AI assistance as a way to improve the process.

AI can potentially extract relevant information from unstructured clinical notes and compare it with trial criteria. This could help research teams identify potentially eligible patients more efficiently.

However, AI-generated eligibility assessments still require appropriate human review, particularly when eligibility decisions involve nuanced clinical judgment.

3. Predicting Treatment Response

Another major opportunity is identifying patients most likely to respond to an investigational therapy.

Machine-learning models can analyze historical treatment outcomes and baseline patient characteristics to search for response patterns.

This could help researchers identify predictive biomarkers or develop more precise inclusion criteria.

For example: Patient characteristics → AI model → predicted response probability → stratified enrollment

This could make trials more informative by ensuring that important biological subgroups are represented.

However, predictive performance in retrospective datasets does not guarantee clinical usefulness. Models must be externally validated and tested prospectively before being relied upon for high-stakes decisions.

AI and Clinical Trial Endpoint Optimization

Patient selection is only half the problem. A clinical trial also needs appropriate endpoints.

An endpoint is a predefined outcome used to evaluate whether a treatment provides benefit or causes harm.

Depending on the disease and study design, endpoints can include:

  • Overall survival
  • Progression-free survival
  • Disease response
  • Biomarker changes
  • Symptom improvement
  • Functional outcomes
  • Quality of life
  • Hospitalization
  • Disease progression
  • Digital or wearable-derived measures

Choosing an endpoint that is too insensitive may make a beneficial therapy appear ineffective. Choosing one that is poorly validated may make results difficult to interpret.

AI is increasingly being investigated as a tool for identifying, predicting, and analyzing clinically meaningful outcomes.

How AI Can Help Optimize Clinical Trial Endpoints

Predicting Relevant Outcomes: AI can analyze historical datasets to determine which baseline characteristics are associated with future outcomes. This can help researchers understand which measurements may be most informative.

Identifying Composite Signals: Some diseases cannot be adequately described by a single measurement. AI can potentially integrate multiple variables into a composite outcome or risk score. For example, researchers could combine laboratory values, imaging findings, symptoms, and functional measures to create a more comprehensive assessment of disease progression.

Detecting Outcomes Earlier: Traditional endpoints can require months or years of follow-up. AI-based predictive models may help identify early signals associated with later clinical outcomes. This could potentially shorten development timelines, although predictive surrogate endpoints require rigorous validation before they can replace established clinical outcomes.

AI and Biomarker-Driven Clinical Trials

Biomarkers are becoming increasingly important in precision medicine. A biomarker can provide information about disease biology, treatment response, or patient risk.

AI can analyze large datasets to identify combinations of biomarkers that may be difficult to detect using conventional statistical approaches.

This could support: Biomarker discovery → patient stratification → targeted enrollment → improved signal detection

The approach may be especially valuable in diseases with substantial biological heterogeneity. In oncology, for example, AI can potentially integrate genomic, transcriptomic, pathological, and imaging information to identify molecularly distinct patient groups. For insights into AI's role in biomarker discovery, see The Role of Artificial Intelligence in Medical Research.

AI in Adaptive Clinical Trial Design

Another emerging area is the combination of AI with adaptive clinical-trial designs.

In a traditional trial, important design decisions are largely fixed before enrollment begins. An adaptive trial can allow predefined modifications based on accumulating data, provided the design maintains statistical validity and protects trial integrity.

Potential adaptations can include:

  • Modifying enrollment
  • Adjusting treatment allocation
  • Dropping ineffective treatment arms
  • Expanding promising patient subgroups
  • Refining dose selection

The FDA's 2025 draft guidance on adaptive clinical trials emphasizes transparent and scientifically justified approaches to planning, conducting, analyzing, and interpreting adaptive studies.

AI could potentially support these processes by rapidly analyzing incoming data and identifying patterns. However, AI should not be treated as an uncontrolled decision-maker. Adaptive rules must be prespecified, statistically justified, and appropriately governed.

Bayesian Methods and AI-Enhanced Trial Design

Bayesian statistical methods are another important component of modern trial design.

Bayesian approaches can incorporate prior information and update statistical beliefs as new evidence becomes available.

In January 2026, the FDA issued draft guidance addressing the appropriate use of Bayesian methodology in clinical trials. The guidance discusses applications including interim analyses, adaptive design decisions, dose selection, and primary inference.

AI and Bayesian methods are not interchangeable. Instead, they can complement one another. AI may identify patterns or generate predictions from complex datasets, while Bayesian statistical methods can provide a formal framework for updating evidence and quantifying uncertainty.

This combination could become increasingly valuable in complex clinical development programs.

AI and Real-World Data

Clinical trials traditionally operate within carefully controlled research environments.

Real-world data provides another source of information.

Examples include:

  • Electronic health records
  • Insurance claims
  • Disease registries
  • Pharmacy data
  • Wearable devices
  • Patient-generated health information

AI can help structure and analyze these datasets.

A 2026 Nature Communications study described an approach combining agentic AI with real-world data to support clinical-trial design, reflecting growing interest in using AI systems to integrate diverse evidence during trial planning.

Real-world data may help researchers understand the characteristics of potential trial populations and evaluate how closely trial participants resemble patients seen in routine clinical practice.

AI for Improving Trial Diversity and Representation

Clinical trials need participants who represent the populations that will eventually use a therapy. However, recruitment can be uneven across demographic and geographic groups.

AI may help identify underserved patient populations and recommend trial sites capable of reaching them.

A 2026 study of an AI-based clinician-to-trial matching framework, DocTr, evaluated more than 24,000 clinicians and 5,000 trials and reported improvements in matching performance while also examining demographic fairness and operational efficiency.

This is an important direction because optimization should not mean simply recruiting patients faster. A well-designed AI system should help recruit appropriate and representative patients.

The FDA's 2025 guidance on enhancing clinical-trial participation specifically encourages broader enrollment across demographic and clinical characteristics so that study populations better reflect the patients who may ultimately receive the treatment.

AI in Oncology Clinical Trials

Cancer research is particularly suited to AI-assisted clinical-trial design because oncology generates enormous amounts of complex data.

A single cancer patient may have:

  • Histopathology images
  • Radiology scans
  • Genomic profiles
  • Molecular biomarkers
  • Treatment histories
  • Laboratory measurements
  • Longitudinal outcomes

AI can potentially integrate these data to support patient stratification.

A 2025 review specifically highlighted AI and machine learning applications across oncology clinical-trial recruitment, trial design, operations, data management, diagnostics, patient stratification, and regulatory decision-making.

This could help accelerate the development of targeted cancer therapies. For related insights on oncology research, see Oncology Research 2026: Immunotherapy, Targeted Therapy, and Precision Medicine Advances.

AI and Digital Endpoints

Wearable and connected devices are creating another opportunity.

Continuous monitoring can generate information about:

  • Physical activity
  • Heart rate
  • Sleep
  • Mobility
  • Symptoms
  • Functional status

Instead of measuring a patient's condition only during scheduled clinic visits, researchers can potentially capture changes over time.

AI can analyze these high-frequency datasets and identify patterns that may be difficult to observe through occasional clinical assessments.

However, digital endpoints must be clinically meaningful, reliable, and appropriately validated. More data does not automatically mean better evidence.

Generative AI in Clinical Trial Design

Generative AI and large language models are opening additional possibilities.

Potential applications include:

  • Drafting trial protocols
  • Summarizing scientific literature
  • Reviewing eligibility criteria
  • Identifying inconsistencies in protocols
  • Supporting site selection
  • Extracting information from clinical notes
  • Assisting with patient-trial matching
  • Generating data queries
  • Supporting trial documentation

A 2025 scoping review of AI in clinical-trial risk assessment found growing use of machine learning, deep learning, causal machine learning, and large language models across safety, efficacy, and operational risk prediction. The authors also emphasized persistent problems such as selection bias, data-quality limitations, and a lack of prospective validation.

Generative AI therefore offers significant efficiency potential, but it should remain subject to human verification.

The Biggest Challenges of AI in Clinical Trials

AI offers enormous potential, but clinical research presents unusually high requirements for reliability.

  • Data Quality: AI models learn from their data. Incomplete, inconsistent, biased, or poorly labeled datasets can produce unreliable predictions.
  • Algorithmic Bias: If historical clinical data underrepresent certain populations, an AI model may reproduce or amplify those disparities. This is particularly important when AI is used for patient selection or trial-site recommendations.
  • Generalizability: A model that performs well in one hospital or dataset may perform poorly elsewhere. Differences in patient demographics, clinical practices, data structures, and disease prevalence can affect performance.
  • Explainability: Researchers and regulators may need to understand why an AI system produced a particular recommendation. Black-box predictions can be difficult to evaluate in high-stakes clinical settings.
  • Privacy and Security: Clinical datasets contain highly sensitive information. AI systems therefore require strong data governance, security controls, and appropriate privacy protections.
  • Prospective Validation: One of the biggest gaps in current research is the difference between promising retrospective performance and demonstrated prospective clinical utility. An algorithm can achieve excellent accuracy on historical data without improving real-world trial outcomes.

The Emerging Regulatory Framework for AI

Regulatory expectations are evolving alongside the technology.

The FDA issued draft guidance in January 2025 describing a risk-based credibility framework for AI models used to support regulatory decisions about drugs and biological products.

The agency has also reported experience with more than 500 submissions containing AI components from 2016 through 2023, demonstrating that AI is already appearing across the medical-product development ecosystem.

Meanwhile, the final ICH E6(R3) Good Clinical Practice guidance, announced by FDA in September 2025, embraces greater flexibility in trial design, technology and data sources while maintaining emphasis on quality by design and participant protection.

Together, these developments suggest that the future of AI-enabled clinical trials will not be defined by technology alone. It will be defined by validated technology used within a robust scientific and regulatory framework.

What Will AI-Powered Clinical Trials Look Like in the Future?

The clinical trial of the future may be considerably more dynamic than today's conventional model.

A potential workflow could look like this:

Real-world data → AI population analysis → biomarker identification → patient stratification → optimized site selection → AI-assisted eligibility screening → adaptive enrollment → continuous endpoint monitoring → real-time data analysis

Such a model could potentially reduce inefficiencies throughout the clinical-development lifecycle.

The FDA's 2026 initiative on real-time clinical trials provides an important example of this broader shift. The agency announced proof-of-concept trials designed to report endpoints and data signals to regulators in real time, alongside plans for a pilot program.

AI could become one of the technologies supporting this more responsive model of clinical research.

AI Will Optimize Trials—But Human Expertise Remains Essential

The most realistic future is not "AI replaces clinical researchers." It is human-AI collaboration.

AI is particularly good at:

  • Processing large datasets
  • Detecting patterns
  • Ranking possibilities
  • Automating repetitive tasks
  • Generating predictions
  • Integrating heterogeneous information

Clinical researchers remain essential for:

  • Understanding biological context
  • Assessing clinical relevance
  • Interpreting unexpected findings
  • Protecting participants
  • Making ethical decisions
  • Evaluating benefit-risk
  • Designing scientifically meaningful studies

The FDA and EMA's good-AI-practice principles explicitly emphasize human-centric design, multidisciplinary expertise, context of use, data governance, performance assessment, and lifecycle management.

That balance will be critical.

AI is beginning to transform clinical-trial design from a largely static process into a more data-driven and potentially adaptive discipline. Its most promising applications include patient stratification, eligibility screening, trial-site selection, biomarker identification, endpoint optimization, adaptive designs, and real-world data analysis.

Recent research demonstrates that AI can improve specific components of clinical-trial operations, while regulatory developments are increasingly establishing principles for trustworthy implementation.

The greatest opportunity may come from combining AI with precision medicine. Instead of enrolling broad populations and searching retrospectively for responders, future trials could increasingly identify biologically meaningful patient groups before enrollment and design endpoints around outcomes that matter most to patients and regulators.

But speed cannot come at the expense of evidence. For AI to genuinely improve clinical research, models must be transparent enough to evaluate, robust enough to generalize, fair enough to serve diverse populations, and validated enough to support high-stakes decisions.

The future of clinical trials is therefore unlikely to be simply AI-driven. It is more likely to be AI-assisted, evidence-based, patient-centered, and continuously optimized. For those considering doctoral research in this area, Top 10 Pharmaceutical Research Topics for PhD offers guidance on selecting impactful research directions.

Continue Exploring Our Blog